Oncology Biosimilars Market
Oncology Biosimilars Market Analysis by Drug Class (G-CSF, Monoclonal Antibody, Hematopoietic Agents), by Disease Indication (Breast Cancer, Colorectal Cancer, Neutropenia, Leukemia) by Distribution Channel, by Region - Global Insights 2022-2032
Analysis of Oncology Biosimilars market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Table of Content
1. Preface 1.1. Market Definition and Scope 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Assumptions & Acronyms Used 2.2. Research Methodology 3. Executive Summary: Global Oncology Biosimilar Market 3.1. Executive Summary 3.2. Market Opportunity Map 3.3. Market Overview 3.4. Key Industry Developments 3.5. Global Oncology Biosimilar Market Size (US$ Mn) Forecast, 2022-2032 3.6. Global Oncology Biosimilar Market Outlook 4. Market Dynamics 4.1. Drivers 4.2. Restraints 4.3. Opportunity 4.4. Key Trends 5. Porter’s Five Force Analysis 6. Oncology Biosimilars: Key Molecules 7. Biosimilars Market Snapshot 8. Cancer Statistics 9. Global Oncology Biosimilars Market Analysis and Forecasts, By Drug Class 9.1. Introduction & Definition 9.2. Key Findings 9.3. Global Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032 9.4. Market Attractiveness by Drug Class 9.5. Global Oncology Biosimilars Market Forecast, by Drug Class, 2022-2032 9.5.1. G-CSF 9.5.2. Monoclonal Antibody 9.5.3. Hematopoietic Agents 9.6. Global Oncology Biosimilars Market Analysis, by Drug Class, 2022-2032 9.7. Key Trends 10. Global Oncology Biosimilars Market Analysis and Forecasts, By Disease Indication 10.1. Introduction & Definition 10.2. Key Findings 10.3. Global Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032 10.4. Market Attractiveness by Disease Indication 10.5. Global Oncology Biosimilars Market Forecast, by Disease Indication, 2022-2032 10.5.1. Breast Cancer 10.5.2. Non-Small Cell lung Cancer 10.5.3. Blood Cancer 10.5.3.1. Leukemia 10.5.3.1.1. Myeloid Leukemia 10.5.3.1.2. Chronic Lymphocytic Leukemia 10.5.3.1.3. Others 10.5.3.2. Non-Hodgkin Lymphoma 10.5.4. Colorectal Cancer 10.5.5. Neutropenia 10.5.6. Others 10.6. Global Oncology Biosimilars Market Analysis, by Disease Indication, 2022-2032 10.7. Key Trends 11. Global Oncology Biosimilars Market Analysis and Forecasts, By Distribution Channel 11.1. Introduction & Definition 11.2. Key Findings 11.3. Global Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032 11.4. Market Attractiveness By Distribution Channel 11.5. Global Oncology Biosimilars Market Forecast, by Distribution Channel, 2022-2032 11.5.1. Hospital Pharmacy 11.5.2. Online Pharmacy 11.5.3. Retail Pharmacy 11.6. Global Oncology Biosimilars Market Analysis, by Distribution Channel, 2022-2032 11.7. Key Trends 12. Global Oncology Biosimilars Market Analysis and Forecasts, By Region 12.1. Global Market Scenario 12.2. Global Oncology Biosimilars Market Value Share, by Region, 2022 and 2032 12.3. Global Oncology Biosimilars Market Attractiveness, by Region, 2022-2032 12.4. Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Region, 2022-2032 12.4.1. North America 12.4.2. Europe 12.4.3. Asia Pacific 12.4.4. Rest of the World 13. North America Oncology Biosimilars Market Analysis and Forecast 13.1. North America Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032 13.2. North America Oncology Biosimilars Market Value Share, by Country, 2022 and 2032 13.3. North America Oncology Biosimilars Market Attractiveness, by Country, 2022-2032 13.4. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032 13.4.1. U.S. 13.4.2. Canada 13.5. North America Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032 13.6. North America Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032 13.7. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032 13.7.1. G-CSF 13.7.2. Monoclonal Antibody 13.7.3. Hematopoietic Agents 13.8. North America Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032 13.9. North America Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032 13.10. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032 13.10.1. Breast Cancer 13.10.2. Non-Small Cell lung Cancer 13.10.3. Blood Cancer 13.10.3.1. Leukemia 13.10.3.1.1. Myeloid Leukemia 13.10.3.1.2. Chronic Lymphocytic Leukemia 13.10.3.1.3. Others 13.10.3.2. Non-Hodgkin Lymphoma 13.10.4. Colorectal Cancer 13.10.5. Neutropenia 13.10.6. Others 13.11. North America Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032 13.12. North America Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032 13.13. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032 13.13.1. Hospital Pharmacy 13.13.2. Online Pharmacy 13.13.3. Retail Pharmacy 13.14. Key Trends 14. Europe Oncology Biosimilars Market Analysis and Forecast 14.1. Europe Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032 14.2. Europe Oncology Biosimilars Market Value Share, by Country, 2022 and 2032 14.3. Europe Oncology Biosimilars Market Attractiveness, by Country, 2022-2032 14.4. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032 14.4.1. U.K. 14.4.2. Germany 14.4.3. France 14.4.4. Italy 14.4.5. Russia 14.4.6. Spain 14.4.7. Rest of Europe 14.5. Europe Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032 14.6. Europe Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032 14.7. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032 14.7.1. G-CSF 14.7.2. Monoclonal Antibody 14.7.3. Hematopoietic Agents 14.8. Europe Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032 14.9. Europe Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032 14.10. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032 14.10.1. Breast Cancer 14.10.2. Non-Small Cell lung Cancer 14.10.3. Blood Cancer 14.10.3.1. Leukemia 14.10.3.1.1. Myeloid Leukemia 14.10.3.1.2. Chronic Lymphocytic Leukemia 14.10.3.1.3. Others 14.10.3.2. Non-Hodgkin Lymphoma 14.10.4. Colorectal Cancer 14.10.5. Neutropenia 14.10.6. Others 14.11. Europe Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032 14.12. Europe Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032 14.13. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032 14.13.1. Hospital Pharmacy 14.13.2. Online Pharmacy 14.13.3. Retail Pharmacy 14.14. Key Trends 15. Asia Pacific Oncology Biosimilars Market Analysis and Forecast 15.1. Asia Pacific Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032 15.2. Asia Pacific Oncology Biosimilars Market Value Share, by Country, 2022 and 2032 15.3. Asia Pacific Oncology Biosimilars Market Attractiveness, by Country, 2022-2032 15.4. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032 15.4.1. China 15.4.2. India 15.4.3. Japan 15.4.4. Australia & New Zealand 15.4.5. Rest of Asia Pacific 15.5. Asia Pacific Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032 15.6. Asia Pacific Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032 15.7. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032 15.7.1. G-CSF 15.7.2. Monoclonal Antibody 15.7.3. Hematopoietic Agents 15.8. Asia Pacific Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032 15.9. Asia Pacific Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032 15.10. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032 15.10.1. Breast Cancer 15.10.2. Non-Small Cell lung Cancer 15.10.3. Blood Cancer 15.10.3.1. Leukemia 15.10.3.1.1. Myeloid Leukemia 15.10.3.1.2. Chronic Lymphocytic Leukemia 15.10.3.1.3. Others 15.10.3.2. Non-Hodgkin Lymphoma 15.10.4. Colorectal Cancer 15.10.5. Neutropenia 15.10.6. Others 15.11. Asia Pacific Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032 15.12. Asia Pacific Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032 15.13. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032 15.13.1. Hospital Pharmacy 15.13.2. Online Pharmacy 15.13.3. Retail Pharmacy 15.14. Key Trends 16. Rest of the World Oncology Biosimilars Market Analysis and Forecast 16.1. Rest of the World Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032 16.2. Rest of the World Oncology Biosimilars Market Value Share, by Country, 2022 and 2032 16.3. Rest of the World Oncology Biosimilars Market Attractiveness, by Country, 2022-2032 16.4. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032 16.4.1. Mexico 16.4.2. Brazil 16.4.3. Rest of the World 16.5. Rest of the World Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032 16.6. Rest of the World Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032 16.7. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032 16.7.1. G-CSF 16.7.2. Monoclonal Antibody 16.7.3. Hematopoietic Agents 16.8. Rest of the World Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032 16.9. Rest of the World Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032 16.10. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032 16.10.1. Breast Cancer 16.10.2. Non-Small Cell lung Cancer 16.10.3. Blood Cancer 16.10.3.1. Leukemia 16.10.3.1.1. Myeloid Leukemia 16.10.3.1.2. Chronic Lymphocytic Leukemia 16.10.3.1.3. Others 16.10.3.2. Non-Hodgkin Lymphoma 16.10.4. Colorectal Cancer 16.10.5. Neutropenia 16.10.6. Others 16.11. Rest of the World Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032 16.12. Rest of the World Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032 16.13. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032 16.13.1. Hospital Pharmacy 16.13.2. Online Pharmacy 16.13.3. Retail Pharmacy 16.14. Key Trends 17. Competition Landscape 17.1. Market Player – Competition Matrix (By Tier and Size of companies) 17.2. Market Share Analysis By Company (2021) 18. Company Profiles 18.1. Sandoz International GmbH 18.1.1. Company Details 18.1.2. Business Overview 18.1.3. Financial Overview 18.1.4. Strategic Overview 18.1.5. SWOT Analysis 18.2. Pfizer, Inc. 18.2.1. Company Details 18.2.2. Business Overview 18.2.3. Financial Overview 18.2.4. Strategic Overview 18.2.5. SWOT Analysis 18.3. Celltrion Inc. 18.3.1. Company Details 18.3.2. Business Overview 18.3.3. Financial Overview 18.3.4. Strategic Overview 18.3.5. SWOT Analysis 18.4. Dr. Reddy’s Laboratories Ltd. 18.4.1. Company Details 18.4.2. Business Overview 18.4.3. Financial Overview 18.4.4. Strategic Overview 18.4.5. SWOT Analysis 18.5. Biocon 18.5.1. Company Details 18.5.2. Business Overview 18.5.3. Financial Overview 18.5.4. Strategic Overview 18.5.5. SWOT Analysis 18.6. Teva Pharmaceutical Industries Ltd. 18.6.1. Company Details 18.6.2. Business Overview 18.6.3. Financial Overview 18.6.4. Strategic Overview 18.6.5. SWOT Analysis 18.7. STADA Arzneimittel AG 18.7.1. Company Details 18.7.2. Business Overview 18.7.3. Financial Overview 18.7.4. Strategic Overview 18.7.5. SWOT Analysis 18.8. Apotex Inc. (Apobiologix) 18.8.1. Company Details 18.8.2. Business Overview 18.8.3. Financial Overview 18.8.4. Strategic Overview 18.8.5. SWOT Analysis 18.9. Intas Pharmaceuticals Ltd. 18.9.1. Company Details 18.9.2. Business Overview 18.9.3. Financial Overview 18.9.4. Strategic Overview 18.9.5. SWOT Analysis 18.10. BIOCAD 18.10.1. Company Details 18.10.2. Business Overview 18.10.3. Financial Overview 18.10.4. Strategic Overview 18.10.5. SWOT Analysis
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Biosimilars Market Snapshot
Table 02: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032
Table 03: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032
Table 04: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, Blood Cancer, 2022-2032
Table 05: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2022-2032
Table 06: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032
Table 07: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Region, 2022-2032
Table 08: Approved Oncology Biosimilars by USFDA in new biosimilars pathway established under BPCIA Act
Table 09: North America Oncology Biosimilars: Pipeline Overview, 2017-2020
Table 10: North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032
Table 11: North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032
Table 12: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032
Table 13: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032
Table 14: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032
Table 15: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2022-2032
Table 16: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2022-2032
Table 17: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032
Table 18: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032
Table 19: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032
Table 20: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032
Table 21: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2022-2032
Table 22: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2022-2032
Table 23: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032
Table 24: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032
Table 25: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, Drug Class, 2022-2032
Table 26: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032
Table 27: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2022-2032
Table 28: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2022-2032
Table 29: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Fig. 01: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, 2022-2032
Fig. 02: Global Oncology Biosimilars Market Value Share, by Drug Class (2021)
Fig. 03: Global Oncology Biosimilars Market Value Share, by Disease Indication (2021)
Fig. 04: Global Oncology Biosimilars Market Value Share, by Distribution Channel (2021)
Fig. 05: Global Oncology Biosimilars Market Value Share, by Region (2021)
Fig. 06: U.S. Prevalence Share (%), By Cancer Type, 2015
Fig. 07: Global Estimation of Cancer, By New Cases & Deaths, 2021
Fig. 08: Global Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032
Fig. 09: Global Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032
Fig. 10: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Monoclonal Antibody, 2022-2032
Fig. 11: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hematopoietic Agents, 2022-2032
Fig. 12: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by G-CSF, 2022-2032
Fig. 13: Global Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032
Fig. 14: Global Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032
Fig. 15: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Breast Cancer, 2022-2032
Fig. 16: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Non-small Cell Lung Cancer, 2022-2032
Fig. 17: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Blood Cancer, 2022-2032
Fig. 18: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Colorectal Cancer, 2022-2032
Fig. 19: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Neutropenia, 2022-2032
Fig. 20: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2022-2032
Fig. 21: Global Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032
Fig. 22: Global Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032
Fig. 23: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacy, 2022-2032
Fig. 24: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Retail Pharmacy, 2022-2032
Fig. 25: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacy, 2022-2032
Fig. 26: Global Oncology Biosimilars Market Value Share, by Region, 2022 and 2032
Fig. 27: Global Oncology Biosimilars Market Attractiveness, by Region, 2022-2032
Fig. 28: North America Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032
Fig. 29: North America Oncology Biosimilars Market Value Share, by Country, 2022 and 2032
Fig. 30: North America Oncology Biosimilars Market Attractiveness, by Country, 2022-2032
Fig. 31: North America Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032
Fig. 32: North America Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032
Fig. 33: Europe Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032
Fig. 34: Europe Oncology Biosimilars Market Value Share, by Country, 2022 and 2032
Fig. 35: Europe Oncology Biosimilars Market Attractiveness, by Country, 2022-2032
Fig. 36: Europe Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032
Fig. 37: Europe Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032
Fig. 38: Europe Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032
Fig. 39: Europe Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032
Fig. 40: Europe Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032
Fig. 41: Europe Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032
Fig. 42: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2022-2032
Fig. 43: Asia Pacific Oncology Biosimilars Market Value Share, by Country, 2022 and 2032
Fig. 44: Asia Pacific Oncology Biosimilars, Market Attractiveness, by Country, 2022-2032
Fig. 45: Asia Pacific Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032
Fig. 46: Asia Pacific Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032
Fig. 47: Asia Pacific Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032
Fig. 48: Asia Pacific Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032
Fig. 49: Asia Pacific Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032
Fig. 50: Asia Pacific Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032
Fig. 51: Rest of the World Oncology Biosimilars, Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2022-2032
Fig. 52: Rest of the World Oncology Biosimilars Market Value Share, by Country, 2022 and 2032
Fig. 53: Rest of the World Oncology Biosimilars, Market Attractiveness, by Country, 2022-2032
Fig. 54: Rest of the World Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032
Fig. 55: Rest of the World Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032
Fig. 56: Rest of the World Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032
Fig. 57: Rest of the World Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032
Fig. 58: Rest of the World Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032
Fig. 59: Rest of the World Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032
Fig. 60: Global Oncology Biosimilars Market Share, by Company, 2021
Fig. 61: Breakdown of Net Sales of Sandoz International GmbH (A Novartis Division), by Franchise, 2021 (%)
Fig. 62: Revenue (US$ Bn) & Y-o-Y Growth (%) of Sandoz International GmbH (A Novartis Division), 2015-2021
Fig. 63: Breakdown of Net Sales of Pfizer, Inc., by Region, 2021 (%)
Fig. 64: Revenue (US$ Bn) & Y-o-Y Growth (%) of Pfizer, Inc., 2015-2021
Fig. 65: Breakdown of Net Sales of Celltrion Inc., by Business Segments, 2021
Fig. 66: Revenue (US$ Mn) & Y-o-Y Growth (%) of Celltrion Inc., 2015-2021
Fig. 67: Breakdown of Net Sales of Dr. Reddy’s Laboratories Ltd., by Business Segments, 2021 (%)
Fig. 68: Revenue (US$ Bn) & Y-o-Y Growth (%) of Dr. Reddy’s Laboratories Ltd., 2015-2021
Fig. 69: Breakdown of Net Sales of Biocon, by Business Segments, 2021 (%)
Fig. 70: Revenue (US$ Mn) & Y-o-Y Growth (%) of Biocon, 2015-2021
Fig. 71: Breakdown of Net Sales of Teva Pharmaceutical Industries Ltd., by Business Segments, 2021 (%)
Fig. 72: Revenue (US$ Bn) & Y-o-Y Growth (%) of Teva Pharmaceutical Industries Ltd., 2015-2021
Fig. 73: Breakdown of Net Sales of STADA Arzneimittel AG, by Business Segments, 2021 (%)
Fig. 74: Revenue (US$ Bn) & Y-o-Y Growth (%) of STADA Arzneimittel AG, 2015-2021
Fig. 75: Revenue (US$ Mn) & Y-o-Y Growth (%) of Intas Pharmaceuticals Ltd., 2015-2021
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request